Ophthalmology Expansion Aequus has launched Zimed PF in Canada with Health Canada approval for lowering intraocular pressure in open angle glaucoma and ocular hypertension. The company has engaged in exclusive distribution partnerships with Scope Ophthalmics and is building an ophthalmics-focused commercial program. Sales opportunities include expanding ophthalmology clinic networks, partnering with eye care payers, and cross-selling to glaucoma specialists leveraging existing distributors and payer insights to improve adherence through the PF formulation.

Adherence Focus Aequus is developing a pipeline in neurology and psychiatry with an emphasis on improved medication adherence via advanced delivery systems. Opportunity for BD to propose co-development or licensing for adherence-oriented formulations with Canadian payers and health systems, and to pursue partnerships that position the company as a preferred supplier for high-need neuro-psychiatry therapies.

Canada Focus The company commercializes in Canada and seeks strategic partnerships to accelerate worldwide potential. This creates opportunities to partner with regional/global pharma for Canada distribution, co-promotion, or licensed products, enabling faster access to markets while leveraging Aequus’ local market insights and payer engagement capabilities.

In licensing Growth Aequus has recently added commercial-stage products via in-licensing and distribution agreements, indicating a growth model that can be complemented by a partner program. Potential upside for BD: target companies with complementary ophthalmology or neuro-psychiatry assets, or co-development deals that align with Canada entry and international expansion.

Growth Readiness With a lean footprint and funding support, Aequus may be open to partner-driven commercialization and revenue-sharing arrangements to scale quickly. The recent revenue activity from Zimed PF demonstrates commercial traction, while the small team signals a reliance on strong partnerships and outsourcing to execute a robust go-to-market in Canada and beyond.